Amicus Therapeutics, Inc. (NASDAQ:FOLD) Director Burke W. Whitman purchased 1,500 shares of the firm’s stock in a transaction dated Thursday, April 1st. The shares were purchased at an average cost of $10.00 per share, for a total transaction of $15,000.00. Following the purchase, the director now directly owns 44,467 shares in the company, valued at $444,670. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
FOLD stock opened at $9.37 on Thursday. The company has a market cap of $2.48 billion, a price-to-earnings ratio of -8.15 and a beta of 1.57. The company has a quick ratio of 5.10, a current ratio of 5.24 and a debt-to-equity ratio of 1.21. The business has a fifty day simple moving average of $10.72 and a 200-day simple moving average of $17.66. Amicus Therapeutics, Inc. has a 52 week low of $8.83 and a 52 week high of $25.39.
Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Sunday, February 28th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). The firm had revenue of $70.57 million for the quarter, compared to analyst estimates of $70.50 million. Amicus Therapeutics had a negative return on equity of 73.81% and a negative net margin of 120.18%. As a group, analysts expect that Amicus Therapeutics, Inc. will post -1.03 earnings per share for the current fiscal year.
FOLD has been the topic of several research analyst reports. Stifel Nicolaus initiated coverage on Amicus Therapeutics in a research note on Monday, March 8th. They set a “hold” rating and a $13.00 price target on the stock. SVB Leerink reduced their target price on Amicus Therapeutics from $15.00 to $13.00 and set a “market perform” rating on the stock in a research note on Monday, March 29th. JPMorgan Chase & Co. lowered Amicus Therapeutics from an “overweight” rating to a “neutral” rating and set a $19.00 target price on the stock. in a research note on Friday, February 12th. Citigroup reduced their target price on Amicus Therapeutics from $27.00 to $16.00 in a research note on Friday, February 12th. Finally, Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell lowered Amicus Therapeutics from a “buy” rating to a “neutral” rating and upped their target price for the company from $20.00 to $27.00 in a research note on Thursday, December 10th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the company’s stock. Amicus Therapeutics has an average rating of “Hold” and a consensus price target of $19.75.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease.
Read More: How a Put Option Works
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.